1. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence;Akaishi;Neurol. Neuroimmunol. Neuroinflamm.,2020
2. P324. Long term efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): results from the roll-over, open-label study SAkuraMoon;Bennett;Mult. Scler.,2023
3. ClinicalTrials.gov. A study to evaluate the safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD). https://clinicaltrials.gov/ct2/show/NCT04660539. Updated December 27, 2023. Last accessed on January 15, 2024.
4. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-mOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial;Cree;Lancet,2019
5. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis;Dixon;Ann. Rheum. Dis.,2012